Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-cell non-Hodgkin's lymphomas (NHL): The impact of histologies of follicular (FL) origin.

被引：0

作者：

Khouri, IF ^{[1
]}

Saliba, RM ^{[1
]}

Acholonu, S ^{[1
]}

Okoroji, GJ ^{[1
]}

Hosing, C ^{[1
]}

Fayad, L ^{[1
]}

Couriel, DR ^{[1
]}

Pro, B ^{[1
]}

Giralt, S ^{[1
]}

Andersson, B ^{[1
]}

Younes, A ^{[1
]}

McLaughlin, P ^{[1
]}

Champlin, RE ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2716

引用

页码：735A / 736A

页数：2

共 50 条

[41] Treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) using a novel mitoxantrone-containing preparative regimen.
Andritsos, Leslie
Suhre, Wendy
Nahirny, Mark
Chase, Ellen
Carroll, Michael
Christian, Jennifer
Miller, Thomas P.
Yeager, Andrew M.
BLOOD, 2006, 108 (11) : 408B - 408B
[42] A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).
Nademanee, A
Molina, A
Forman, SJ
Kogut, N
Yamauchi, D
An, L
White, CA
Raubitschek, A
BLOOD, 2002, 100 (11) : 182A - 182A
[43] A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)
Joyce, RM
Regan, M
Ottaway, J
Umiel, T
Tetreault, JC
Levine, J
McDermott, D
Hurley, D
Giallombardo, N
Smith, T
Lamontagne, D
Uhl, L
Avigan, D
ANNALS OF ONCOLOGY, 2003, 14 : 21 - 27
[44] Early autologous stem cell transplantation (ASCT) versus conventional first-line chemotherapy in high-risk aggressive non-Hodgkin's lymphomas (NHL): An Italian Multicenter randomized trial.
Gherlinzoni, F
Martelli, M
Tura, S
BLOOD, 2000, 96 (11) : 481A - 481A
[45] High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin's and non-Hodgkin lymphoma: monocentre study and long-term outcome in 330 patients
Donnini, I.
Rigacci, L.
Puccini, B.
Guidi, S.
Nozzoli, C.
Benelli, G.
Gozzini, A.
Bartolozzi, B.
Bosi, A.
BONE MARROW TRANSPLANTATION, 2012, 47 : S444 - S444
[46] High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
Salar, A
Martino, R
Perea, G
Ribera, JM
López-Guillermo, A
Guardia, R
Escoda, L
Altés, A
Sierra, J
Montserrat, E
HAEMATOLOGICA, 2002, 87 (10) : 1028 - 1035
[47] A prospective phase II comparison of autologous (ASCT) or allogeneic (ALLOSCT) blood stem cell transplantation for indolent B-cell non-Hodgkin lymphoma (NHL) using rice reinduction, then high dose Fludarabine and Busulfan conditioning
Stewart, D. A.
Russell, J.
Bahlis, N.
Hasagawa, W.
Voralia, M.
ANNALS OF ONCOLOGY, 2008, 19 : 184 - 185
[48] Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)
Wei, J. I. A.
Xiao, Min
Mao, Zekai
Cao, Yang
Xiao, Yi
Meng, Fankai
Zhang, Yicheng
Zhou, Jianfeng
Huang, Liang
BLOOD, 2021, 138
[49] Chemosensitive transformed follicular non-Hodgkin's lymphoma (NHL) is a firm-indication for high-dose therapy and autologous stem cell transplantation. A study from the EBMT registry.
Williams, CD
Taghipour, G
Lister, TA
Blystaad, AM
Coiffier, B
Goldstone, AH
BLOOD, 1996, 88 (10) : 2727 - 2727
[50] Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Hasenkamp, Justin
Hess, Georg
Hertenstein, Bernd
Dreger, Peter
Uharek, Lutz
Gramatzki, Martin
Schubert, Joerg
Wulf, Gerald
Truemper, Lorenz
Schmitz, Norbert
Glass, Bertram
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →